# Tacrolimus Treatment for Refractory PRCA

> **NCT03540472** · PHASE4 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Pure Red Cell Aplasia

## Interventions

- **DRUG:** tacrolimus

## Key facts

- **NCT ID:** NCT03540472
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-10
- **Primary completion:** 2018-12-10
- **Final completion:** 2020-06-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2018-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03540472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03540472, "Tacrolimus Treatment for Refractory PRCA". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03540472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*